CINECA IRIS Institutional Research Information System

VALABREGA, Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.256
EU - Europa 3.936
AS - Asia 3.123
SA - Sud America 172
AF - Africa 94
OC - Oceania 78
Continente sconosciuto - Info sul continente non disponibili 10
Totale 13.669
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.074
CN - Cina 1.364
IT - Italia 1.190
SG - Singapore 721
DE - Germania 398
GB - Regno Unito 396
IE - Irlanda 371
FR - Francia 291
SE - Svezia 279
JP - Giappone 259
FI - Finlandia 152
IN - India 150
ES - Italia 146
CA - Canada 134
PL - Polonia 128
KR - Corea 120
VN - Vietnam 120
BR - Brasile 111
UA - Ucraina 109
NL - Olanda 77
ID - Indonesia 76
AU - Australia 67
DK - Danimarca 60
HK - Hong Kong 60
TR - Turchia 56
BE - Belgio 51
AT - Austria 50
TW - Taiwan 47
CH - Svizzera 45
MX - Messico 45
RU - Federazione Russa 40
EG - Egitto 35
PT - Portogallo 30
TH - Thailandia 28
IR - Iran 25
RO - Romania 25
NG - Nigeria 23
IL - Israele 21
PE - Perù 21
GR - Grecia 16
SA - Arabia Saudita 15
AR - Argentina 14
CZ - Repubblica Ceca 14
HR - Croazia 13
HU - Ungheria 13
UZ - Uzbekistan 13
CO - Colombia 12
CL - Cile 11
NZ - Nuova Zelanda 11
NO - Norvegia 9
MY - Malesia 8
MA - Marocco 7
AM - Armenia 6
AP - ???statistics.table.value.countryCode.AP??? 6
KW - Kuwait 6
PK - Pakistan 6
SN - Senegal 6
TN - Tunisia 6
BY - Bielorussia 5
LU - Lussemburgo 5
SK - Slovacchia (Repubblica Slovacca) 5
ZA - Sudafrica 5
EU - Europa 4
LT - Lituania 4
SD - Sudan 4
BG - Bulgaria 3
EC - Ecuador 3
PH - Filippine 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
BF - Burkina Faso 2
EE - Estonia 2
GE - Georgia 2
JO - Giordania 2
KZ - Kazakistan 2
LB - Libano 2
MO - Macao, regione amministrativa speciale della Cina 2
UG - Uganda 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CU - Cuba 1
ET - Etiopia 1
IQ - Iraq 1
IS - Islanda 1
JM - Giamaica 1
KE - Kenya 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
OM - Oman 1
PA - Panama 1
QA - Qatar 1
SI - Slovenia 1
ZW - Zimbabwe 1
Totale 13.669
Salva come PNG Salva come JPEG
Città #
Chandler 626
Fairfield 448
Singapore 408
Dublin 358
Beijing 357
Houston 346
Santa Clara 343
Ashburn 332
Woodbridge 247
Ann Arbor 240
Seattle 216
Wilmington 186
Cambridge 170
Torino 155
Nyköping 137
Redwood City 127
Shanghai 114
Turin 112
Columbus 107
Jacksonville 102
Munich 93
Princeton 91
Guangzhou 90
Medford 90
Milan 90
Villeurbanne 86
Dearborn 85
New York 79
Rome 78
Jakarta 72
Warsaw 72
Pisa 67
Nanjing 65
Dong Ket 64
Tokyo 61
London 44
Boston 42
Fremont 41
Helsinki 40
Hangzhou 39
Los Angeles 38
Silver Spring 37
Boardman 35
Nuremberg 34
San Diego 31
Wuhan 31
Chicago 28
Asyut 27
Duncan 27
Hong Kong 27
Taipei 27
Ottawa 26
Toronto 26
Chengdu 25
Madrid 24
São Paulo 23
Brussels 22
Vienna 21
Abuja 20
Kunming 20
Delhi 18
Paris 18
Sydney 18
Washington 18
Jinan 17
Barcelona 16
Changsha 16
Hefei 16
Seoul 16
Phoenix 15
Dallas 14
Hebei 14
Istanbul 14
Osaka 14
Padova 14
Shenyang 14
Upper Marlboro 14
Amsterdam 13
Bangkok 13
Lappeenranta 13
New Delhi 13
Tianjin 13
Worcester 13
Zhengzhou 13
Ankara 12
Bologna 12
Harbin 12
Norwalk 12
Riverton 12
St Louis 12
Valencia 12
Xian 12
Berlin 11
Florence 11
Gothenburg 11
Naples 11
Philadelphia 11
Poznan 11
Verona 11
Birmingham 10
Totale 7.609
Salva come PNG Salva come JPEG
Nome #
PARP Inhibitors in Ovarian Cancer 2.748
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 792
New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer 529
Metastatic breast cancer subtypes and central nervous system metastases. 297
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 294
Modeling ErbB2-p130Cas interaction to design new potential anticancer agents. 253
Checkpoint inhibitors in endometrial cancer: Preclinical rationale and clinical activity 242
Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis 215
Androgen receptor status predicts development of brain metastases in ovarian cancers 209
p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy 202
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer 197
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy 179
Adoptive immunotherapy against ovarian cancer 177
Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions 175
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer 168
Immune checkpoint inhibitors: A new opportunity in the treatment of ovarian cancer? 166
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. 157
Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer? 155
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature 145
A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience 140
Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: A retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer 137
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer 137
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy 137
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers 133
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy 133
Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience 133
Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications 132
Abstract 3102: Identification of actionable cancer genes and treatment options for metastatic ovarian carcinomas using patient-derived xenografts and PDX-derived tumor cells 130
Reprogramming T-cells for adoptive immunotherapy of ovarian cancer 122
Immune checkpoint inhibitors in epithelial ovarian cancer: An overview on efficacy and future perspectives 118
The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005 114
Recent advances in the development of breast cancer vaccines. 112
Assays of conventional chemotherapeutics and targeted drugs for ovarian cancer using patient derived models 112
Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series 111
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. 110
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib 108
PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma 106
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity 105
ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. 100
Identification of Actionable Cancer Genes and Treatment Options for Metastatic Ovarian Carcinomas using Patient Derived Xenografts (PDXs) and PDX Derived Tumor Cells (PDTCs) 100
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer 98
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy 98
Clinical implications of DNA repair defects in high-grade serous ovarian carcinomas 97
Ovarian cancer immunotherapy: Turning up the heat 97
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer 96
Role of cyclin-dependent kinase inhibitors in endometrial cancer 90
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. TOP2A as marker of response to PLD in ovarian cancer 89
Women with synchronous or metachronous lung and ovarian cancer: A multi-institutional report 86
Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents (Scientific Reports, (2019), 9, 1, (3089), 10.1038/s41598-019-39510-w) 85
Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience 84
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality 79
Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial 78
A Retrospective Analysis of the Activity and Safety of Oral Etoposide in Heavily Pretreated Metastatic Breast Cancer Patients. 77
Is there a role for immunotherapy in ovarian cancer? 77
Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers 77
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21) 75
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers 72
TGFalpha expression impairs Trastuzumab-induced HER2 downregulation 70
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 70
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey 70
Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007 68
Veliparib: a new therapeutic option in ovarian cancer? 67
Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. 65
Biomarkers of central nervous system involvement from epithelial ovarian cancer 65
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time? 65
Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer 64
Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study 64
Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells 64
Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition 64
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 61
Immunotherapy in cervix cancer 61
Differences in parp inhibitors for the treatment of ovarian cancer: Mechanisms of action, pharmacology, safety, and efficacy 60
Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. 59
Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. 59
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22) 57
Controversies in breast cancer: adjuvant and neoadjuvant therapy 56
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors 55
Translational research in ovarian cancer 54
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer 54
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era 53
From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia 53
Multitarget drugs: the present and the future of cancer therapy 51
Impact of covid-19 in gynecologic oncology: A nationwide italian survey of the sigo and mito groups 51
Role of trastuzumab in the management of HER2-positive metastatic breast cancer. 50
Trastuzumab-based combination therapy for breast cancer 49
ASO Visual Abstract: Clinical and Histopathologic Predictors Signaling Recurrence of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers 47
Potential of afatinib in the treatment of patients with HER2-positive breast cancer. 47
Trastuzumab treatment in breast cancer 46
Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities. 46
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 45
Searching for prognostic markers for Stage I epithelial ovarian cancer: A role for systemic inflammatory markers 45
Trastuzumab Beyond Disease Progression: Case Closed? 43
Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? 41
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study 38
Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients. 36
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society 33
Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer. 32
Lynch syndrome-associated endometrial cancer patient with a rare novel germline likely pathogenic variant of MSH2 gene: A case report 30
Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience 29
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors 28
Totale 13.550
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.822
article - articoli 0
book - libri 0
conference - conferenze 1.134
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.956
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020405 0 0 0 0 0 0 0 0 136 93 67 109
2020/20212.148 67 172 270 172 175 173 157 153 178 204 140 287
2021/20222.082 149 132 103 161 135 144 157 170 161 148 329 293
2022/20232.425 211 222 94 198 229 481 184 152 257 86 172 139
2023/20241.959 211 221 104 147 145 257 158 166 40 158 136 216
2024/20252.215 72 180 149 231 671 266 138 231 277 0 0 0
Totale 13.982